Search results for "INCIDENCE"

showing 10 items of 2270 documents

Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.

2019

Abstract Introduction and objectives Non-alcoholic steatohepatitis (NASH) indication of liver transplant (LT) has increased recently, whereas alcoholic cirrhosis remains a major indication for LT. To characterize NASH-related cases and to compare the post-transplant outcome of these two conditions represents our major objective. Material and methods Patients undergoing LT for NASH between 1997 and 2016 were retrieved. Those transplanted between 1997 and 2006 were compared to an “age and LT date” matched group of patients transplanted for alcoholic cirrhosis (ratio 1:2). Baseline features and medium-term outcome measures were compared. Results Of 1986 LT performed between 1997 and 2016, 40 (…

Liver CirrhosisMaleAlcoholic liver diseaseCirrhosisHepatocellular carcinomamedicine.medical_treatmentSpecialties of internal medicineLiver transplantationGastroenterologyCohort Studies0302 clinical medicinePostoperative ComplicationsLiver Cirrhosis AlcoholicNon-alcoholic Fatty Liver DiseaseCause of DeathHyperuricemiaRenal InsufficiencyCardiovascular risk factorsIncidence (epidemiology)Liver NeoplasmsGeneral MedicineMiddle AgedSurvival RateTreatment OutcomeRC581-951Cardiovascular Diseases030220 oncology & carcinogenesisHepatocellular carcinomaHypertension030211 gastroenterology & hepatologyFemaleAlcoholAdultmedicine.medical_specialtyCarcinoma HepatocellularHyperuricemia03 medical and health sciencesYoung AdultInternal medicinemedicineDiabetes MellitusHumansObesityAgedDyslipidemiasRetrospective StudiesHepatologybusiness.industrynutritional and metabolic diseasesOverweightmedicine.diseasedigestive system diseasesLiver TransplantationSpainSteatohepatitisNeoplasm Recurrence LocalbusinessDyslipidemiaAnnals of hepatology
researchProduct

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.

2018

Background & Aims: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus–associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. Methods: We collected data from a large prospective study of 2,249 consecutive patients (mean age = 65.4 years, 56.9% male) with hepatitis C virus–associated cirrhosis (90.5% with Child-Pugh class A and 9.5% with Child-Pugh class B) treated with DAAs from March 2015 through July 2016 at 22 academic and community liver centers in Sicily, Italy. HCC occurren…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaSustained Virologic ResponseHepacivirusGastroenterology0302 clinical medicineRESIST-HCVRisk FactorsHepatocellular Carcinoma (HCC)MedicineLiver Cancer RiskProspective StudiesProspective cohort studySettore MED/12 - GastroenterologiaIncidence (epidemiology)IncidenceLiver NeoplasmsGastroenterologyHepatitis CMiddle AgedCirrhosis; Direct Antiviral Agents (DAAs); Hepatocellular Carcinoma (HCC); RESIST-HCV; Sustained Virological Response (SVR); hepatitis C Virus (HCV); liver cancer risk; reduction; sofosbuvirCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomahepatitis C Virus (HCV)030211 gastroenterology & hepatologyFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularDirect Antiviral Agents (DAAs)Liver CirrhosiRESIST-HCV Liver Cancer Risk Reduction SofosbuvirAntiviral AgentsFollow-Up Studie03 medical and health sciencesInternal medicineHumansIn patientSustained Virological Response (SVR)AgedReductionAntiviral AgentHepaciviruHepatologybusiness.industryProportional hazards modelRisk FactorHepatitis C Chronicmedicine.diseasedigestive system diseasesProspective StudieChild-Pugh Class BSofosbuvirbusinessFollow-Up Studies
researchProduct

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

2018

Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous …

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepatocellular carcinomaDirect antiviral agentsDIRECT ACTING ANTIVIRALSGastroenterologyCohort Studies0302 clinical medicineRisk FactorsChronicIncidence (epidemiology)Liver NeoplasmsGastroenterologyMiddle AgedHepatitis CTumor recurrenceCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinoma; Aged; Antiviral Agents; Carcinoma Hepatocellular; Cohort Studies; Disease Progression; Female; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Risk Factors; alpha-Fetoproteins; Sustained Virologic ResponseItalyLocalCirrhosis030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease ProgressionPortal hypertension030211 gastroenterology & hepatologyFemalealpha-FetoproteinsCohort studymedicine.medical_specialtyCarcinoma HepatocellularEarly RecurrenceAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedCirrhosiHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseasedigestive system diseasesNeoplasm RecurrenceDirect antiviral agentNeoplasm Recurrence LocalCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinomabusiness
researchProduct

Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A…

2010

The incidence of de novo development of esophageal varices (EV) in patients with compensated liver cirrhosis has been determined by few studies in the short term and never in the long term. The aims of the present study were to determine the incidence and the risk factors associated with the development of EV and to assess whether antiviral treatment and achievement of sustained virologic response (SVR) may prevent de novo EV development in patients with HCV-induced cirrhosis. We studied 218 patients with compensated EV-free, HCV-induced cirrhosis consecutively enrolled between 1989 and 1992 at three referral centers in Milan, Italy. Endoscopic surveillance was performed at 3-year intervals…

Liver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularCirrhosisEsophageal and Gastric VaricesAntiviral AgentsGastroenterologyLiver diseaseEsophageal varicesRisk FactorsInternal medicinemedicineHumansProspective StudiesProspective cohort studyAgedHepatologybusiness.industryIncidenceLiver NeoplasmsHazard ratiovirus diseasesHepatitis CHepatitis C ChronicMiddle AgedHepatologymedicine.diseasedigestive system diseasesDiscontinuationItalyFemalebusinessFollow-Up StudiesCirrhosis HCV
researchProduct

Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance

2011

BACKGROUND: The aetiological factors of hepatocellular carcinoma may vary over time. AIMS: The study assessed the potential impact of the aetiological factors on the effectiveness of surveillance in real-world patients. METHODS: Multicentre, cross-sectional study enrolling consecutive hepatocellular carcinoma cases during a six month period. RESULTS: 1733 cases (1311 prevalent and 422 incident) were recruited (mean age 68.6 years; 46.1% cases over 70 years; 73.9% males; 95.3% with cirrhosis); 63.0% were hepatitis C virus positive and 23.7% were virus negative. Amongst incident HCCs, 34.5% were single ≤3cm and 54.4% met the Milan criteria; 61.6% were diagnosed during surveillance; virus nega…

Liver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularEpidemiologyHepatocellular carcinomaCross-sectional studyCancer stageCancer stage; Epidemiology; Hepatitis; Hepatocellular carcinoma; Surveillance; Age Distribution; Aged; Carcinoma Hepatocellular; Cross-Sectional Studies; Female; Hepatitis B Surface Antigens; Hepatitis C Antibodies; Humans; Incidence; Italy; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prevalence; Ultrasonography; Population Surveillance; Hepatology; GastroenterologyMilan criteriaHepatitisAge DistributionInternal medicineEpidemiologyPrevalenceCarcinomaHumansMedicineHCCAgedUltrasonographyHepatitisHepatitis B Surface AntigensSurveillanceHepatologybusiness.industryIncidenceIncidence (epidemiology)CarcinomaLiver NeoplasmsCancer stage Epidemiology Hepatitis Hepatocellular carcinoma SurveillanceGastroenterologyHepatocellularHepatitis C AntibodiesMiddle Agedmedicine.diseaseETIOLOGYSurgeryCross-Sectional StudiesLogistic ModelsItalyHepatitis C Virus PositivePopulation SurveillanceHepatocellular carcinomaMultivariate AnalysisSURBVEILLANCEFemalebusiness
researchProduct

Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension

2010

Background: Oesophagogastroduodenoscopy is currently recommended for the screening of varices in cirrhosis. In addition to the assessment of varices, oesophagogastroduodenoscopy can detect conditions that, while unrelated to portal hypertension, may require treatment. Aims: We evaluated in a large cohort of cirrhotic patients the prevalence of upper digestive findings other than oesophagogastric varices, the associations between upper gastrointestinal findings, portal hypertension and features of cirrhosis, and the incidence of new lesions in the course of a surveillance program. Methods: Analysis of the records of 611 consecutive cirrhotic patients undergoing oesophagogastroduodenoscopy fo…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPepticPortal hypertensive gastropathyAdenocarcinomaEsophageal and Gastric VaricesGastroenterologyAsymptomaticHelicobacter InfectionsPolypsStomach NeoplasmsInternal medicineHypertension PortalPrevalenceHumansMedicineEndoscopy Digestive SystemStomach UlcerVascular DiseasesAgedMetaplasiaHelicobacter pyloriHepatologymedicine.diagnostic_testbusiness.industrycirrhosisIncidence (epidemiology)GastroenterologyMiddle Agedmedicine.diseaseEndoscopyDuodenal UlcerGastritisPortal hypertensionFemalemedicine.symptombusinessVaricesDigestive and Liver Disease
researchProduct

Nontumorous portal vein thrombosis in liver cirrhosis: Possible role of β-blockers

2018

<b><i>Objective:</i></b> Nonselective β-blockers (NSBB) are used in liver cirrhosis (LC) to prevent variceal bleeding because they decrease portal pressure. A main risk factor for the development of portal vein thrombosis (PVT) in LC is decreased portal vein inflow velocity. The aim of our study was to examine retrospectively the incidence of PVT and its correlation with the use of β-blockers in a cohort of LC patients. <b><i>Subjects and Methods:</i></b> Data from 230 LC patients (90% Child-Pugh class A), who had been followed up for at least 5 years, were reviewed. The diagnosis of PVT was made by ultrasound. The presence of PVT was evaluate…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaPortal venous pressureCirrhosis complicationAdrenergic beta-AntagonistsNonselective β-blockerGastroenterologySeverity of Illness Index03 medical and health sciences0302 clinical medicineEsophageal varicesRisk FactorsInternal medicineAscitesmedicineHumansRisk factorBleeding prevention therapyRisk of thrombosiAgedRetrospective StudiesAged 80 and overVenous ThrombosisUnivariate analysisOriginal Paperbusiness.industryPortal VeinIncidence (epidemiology)Medicine (all)General MedicineMiddle Agedmedicine.diseasePortal vein thrombosisLogistic ModelsItaly030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemalemedicine.symptombusiness
researchProduct

Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy

2019

BACKGROUND Systemic inflammation is a driving force for the development of hepatic encephalopathy and recent studies demonstrated that elevated Interleukin-6 (IL-6) serum levels are associated with the presence of minimal hepatic encephalopathy in patients with liver cirrhosis. AIM To test the hypothesis that IL-6 is a suitable marker to identify patients with liver cirrhosis at high risk for the development of overt hepatic encephalopathy. METHODS 201 patients were included into this prospective cohort study and were followed for a mean time of 322 days. Covert hepatic encephalopathy was diagnosed according to the West-Haven criteria (hepatic encephalopathy grade 1) and with the portosyste…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSystemic inflammationSensitivity and SpecificityGastroenterologyDiagnosis Differential03 medical and health sciencesLiver disease0302 clinical medicineRisk FactorsInternal medicineHumansMedicinePharmacology (medical)Cumulative incidenceProspective Studies030212 general & internal medicineInterleukin 6Prospective cohort studyPortosystemic encephalopathyHepatic encephalopathyAgedInflammationHepatologybiologyInterleukin-6business.industryGastroenterologyMiddle Agedmedicine.diseaseUp-RegulationC-Reactive ProteinHepatic Encephalopathybiology.proteinFemale030211 gastroenterology & hepatologymedicine.symptombusinessBiomarkersAlimentary Pharmacology & Therapeutics
researchProduct

Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases.

2006

In 2001, 6,999 anti-HCV positive subjects referred to 79 Italian hospital in a 6 months enrollment period were evaluated. Of them, 5,632 (80.5%) tested anti-HCV positive alone, 1,163 (16.6%) reported also an excessive alcohol intake, and 204 (2.9%) were also HBsAg positive. Normal biochemistry was observed in 7.8% of cases, chronic hepatitis in 67.9% of cases, liver cirrhosis in 18.9% of cases, and hepatocellular carcinoma in 3.6% cases. HCV positive subjects with excessive alcohol intake were statistically significantly younger, of male sex, and having more severe liver disease than those without excessive alcohol intake. Adjusting for the confounding effect of age and sex by multiple logi…

Liver CirrhosisMalemedicine.medical_specialtyHBsAgCirrhosisCarcinoma HepatocellularAlcohol DrinkingHepacivirusHepacivirusChronic liver diseaseHCV PositiveLiver diseaseVirologyInternal medicinePrevalenceMedicineHumansHepatologybiologybusiness.industryIncidence (epidemiology)Incidencechronic liver diseaseHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseSurgeryHCV infectionInfectious DiseasesItalyHepatocellular carcinomaRegression AnalysisFemalebusinessJournal of viral hepatitis
researchProduct

Detection of hepatitis C virus replication in ovarian metastases of a patient with hepatocellular carcinoma.

1994

Hepatocellular carcinoma is one of the most common human cancers with an annual incidence of about 1,000,000 cases worldwide. Although hepatocellular carcinoma is predominant in hepatitis B virus endemic areas, it has also become a major problem in Europe, Japan and North America in close association with the increasing incidence of hepatitis C virus infection. The pathogenetic role of hepatitis C virus infection in the development of HBsAg-negative hepatocellular carcinoma needs to be clarified. In this paper the case of a 66-year-old HBsAg-negative and anti-HCV positive female who developed hepatocellular carcinoma in a cirrhotic liver is reported. After 1 year of follow up, urgent laparo…

Liver CirrhosisPathologymedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusHepacivirusOvaryHepacivirusmedicine.disease_causeVirus ReplicationGastroenterologyVirusMetastasisFlaviviridaeInternal medicinemedicineHumansAgedHepatitis B virusOvarian NeoplasmsHepatitis B Surface AntigensHepatologybiologyIncidenceLiver Neoplasmsmedicine.diseasebiology.organism_classificationdigestive system diseasesmedicine.anatomical_structureHepatocellular carcinomaRNA ViralFemaleTomography X-Ray ComputedJournal of hepatology
researchProduct